Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
By P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto, J. Kastelein, W. Koenig, Peter Libby, A. Lorenzatti, Jean G Macfadyen and 4 more. New England Journal of Medicine, 2008
6,106 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/6074c938a818d4c341479e23370ed6531431d7b6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Peter Libby
- George Davey Smith
- A. Lichtman
- D. Lloyd‐Jones
- G. Hansson
- S. Grundy
- Børge G. Nordestgaard
- N. Verweij
In Epidemiology
- Peter Libby
- P. Ridker
- Børge G. Nordestgaard
- G. Hansson
- George Davey Smith
- V. Z. Rocha
- S. Grundy
- A. Varbo
In Surgery
Citations in the corpus
- National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, methodology): “5% 10-year risk projected from rates observed over shorter observation periods).(74,76,266) The threshold of $10% 10-year risk for a hard CHD event using the ATP III Framingham Risk calculator was selected because it is roughly equivalent to 15% ASCVD risk, assuming the risk for stroke represents ap”
- Guidelines for the Primary Prevention of Stroke (2011, positive): “0 mg/L were randomized to receive rosuvastatin 20 mg daily or placebo and followed up for the occurrence of the combined primary end point of MI, stroke, arterial revascularization, hospitalization for unstable angina, or death resulting from cardiovascular causes.(657) The rates were reduced by a h”
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, background): “In JUPITER, the 44% risk reduction with the use of rosuvastatin was associated with a decline in hs-CRP.(344) Thus, the biology of CRP levels in HIV infection is complicated and likely driven by multiple factors.”